Tecadenoson

Research use only, not for human use.

Tecadenoson is a selective agonist of A1 adenosine receptor.

Tecadenoson is a selective agonist of A1 adenosine receptor.

In the atrial-paced isolated heart, Tecadenoson is approximately 5 fold more potent to prolong the stimulus-to-His bundle (S-H interval), a measure of slowing AV nodal conduction (EC50=41?nM) than to increase coronary conductance (EC50=200?nM). At concentrations of Tecadenoson (40?nM) and diltiazem (1?μM) that causes equal prolongation of S-H interval (～10?ms), diltiazem, but not Tecadenoson, significantly reduces left ventricular developed pressure (LVP) and markedly increases coronary conductance. Tecadenoson shortens atrial (EC50=73?nM) but not the ventricular monophasic action potentials (MAP).

In atrial-paced anaesthetized guinea-pigs, intravenous infusions of Tecadenoson and diltiazem causes nearly equal prolongations of P-R interval. Tecadenoson (2, 5, 20 μg/kg i.p.) causes a rapid and sustained dose-dependent decrease in NEFA at doses that do not cause bradycardia. Tecadenoson given at 50 μg/kg causes a significant bradycardia (50% decrease in heart rate at 25 min.

CVT-510

Apoptosis

Adenosine Receptor

A1

——

——

204512-90-3

337.33

C14H19N5O5

>98% (HPLC)

DMSO:155 mg/mL (459.49 mM)

OC[C@H]([C@H]([C@H]1O)O)O[C@H]1n1c2ncnc(N[C@H]3COCC3)c2nc1

——

(-20℃)

With Ice Pack

≥ 2 years